B.N.Rathi Securities Ltd.

Company Profile

Smart Quotes

STRIDES PHARMA SCIENCE LTD.

NSE : STARBSE : 532531ISIN CODE : INE939A01011Industry : Pharmaceuticals & DrugsHouse : Private

BSE876.45-2.6 (-0.3 %)

PREV CLOSE ( ) 879.05

OPEN PRICE ( ) 880.15

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 18421

TODAY'S LOW / HIGH ( )868.90 899.20

52 WK LOW / HIGH ( )330.35 903.8

NSE876.70-6.75 (-0.76 %)

PREV CLOSE( ) 883.45

OPEN PRICE ( ) 884.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 876.70 (445)

VOLUME 150685

TODAY'S LOW / HIGH( ) 866.30 900.00

52 WK LOW / HIGH ( )330 902.4

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-06 1990

Management Info

Arun Kumar - Chairman Arun Kumar - Managing Director

Registered Office

Address 201, Devavrata,Sector-17,Vashi,
Navi Mumbai,
Maharashtra-400703

Phone 022-27892924 / 3199

Email corpcomm@strides.com

Website www.strides.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE, MCX

NEWS

10Apr Strides Pharma Science gains as its ar
Strides Pharma Science is currently trading at Rs. 842.10, up by 4.20 po..

09Apr Strides Pharma Science’s arm gets USFD
Strides Pharma Science’s step-down wholly owned subsidiary -- Strides Ph..

09Apr Strides Pharma Science informs about p
Strides Pharma Science has informed that it attached a press release tit..

06Apr USFDA completes cGMP inspection at Che
United States Food and Drug Administration (USFDA) has completed a routi..

06Apr Strides Pharma Science informs about c
Strides Pharma Science has informed that a routine current Good Manufact..

Financials

in Millions

	QTR Dec 23	ANNUAL 23
Net Profit	25.42	46.82
Gross Profit	35.2	-647.6
Operating Profit	743.41	1825.43
Net Sales	5200.15	18544.96

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Divi's Lab (BSE) 4025.35 (4.81%)	M.Cap ( in Cr)106860.39
Sanofi India (BSE) 8278.10 (1.76%)	M.Cap ( in Cr)19064.98
Abbott India (BSE) 25864.85 (0.54%)	M.Cap ( in Cr)54961.00
Astrazeneca Pharma I (BSE) 5415.40 (2.18%)	M.Cap ( in Cr)13538.50
Glaxosmithkline Phar (BSE) 2132.75 (3.26%)	M.Cap ( in Cr)36130.07

Shareholding Pattern

	NON-INSTITUTION	31.5%
	PROMOTERS	25.88%
	MUTUAL FUNDS/UTI	10.57%
	FI/BANKS/INSURANCE	5.78%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Quant Value Fund-Reg(G)	3.06
Aditya Birla SL Mfg. Equity Fund-Reg(G)	2.79
Aditya Birla SL Pharma & Healthcare Fund-Reg(G)	2.28
Aditya Birla SL Pure Value Fund(G)	2.10
Aditya Birla SL Retirement Fund-30-Reg(G)	1.70
Aditya Birla SL Special Opp Fund-Reg(G)	1.53
Quant Business Cycle Fund-Reg(G)	1.52

Investor Alert

1) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. 2) For Stock Broking Transaction 'Prevent unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day...Issued in the interest of Investors. 3) For Depository Transaction 'Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day...Issued in the interest of investors. 4) No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account. 5) Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website. 6) This is to inform that we B N Rathi securities Ltd not required to have a Business Continuity/DR plan under the existing regulatory provisions.

ATTENTION INVESTORS | KYC | IPO

Prevent Unauthorised transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/DP. Receive information of your transactions directly from Exchanges/Depositories on your mobile/email at the end of the day. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account......Issued in the interest of investors. SEBI Circular - Investor Grievance Redress Mechanism - New Policy Measures. Kindly refer at Policies.

KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account

REGISTRATION NOS: SEBI Registration No: INZ000160834 (BSE-3233 | NSE-07141| MCX-56475) CDSL : SEBI Regn No. IN-DP-612-2021. AMFI-Registered Mutual Fund Distributor: B.N.Rathi Securities Ltd - ARN-77516: (B.N.Rathi is just acting as distributor. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism.) CIN: L65993TG1985PLC005838

GRIEVANCE CONTACT Investor Grievance Contact: investorgrievances@bnrsecurities.com | DP Investor Grievance: investorgrievances@bnrsecurities.com Investor Protection and Arbitration Exchange Circulars and Rules - NSE,BSE and MCX.

In case of member having a website, member has created awareness amongst clients / investors with regard to procedure of pledge/ re-pledge of securities and displayed the guidelines on the homepage of their respective websites at a prominent place as required in Exchange circular ref no. NSE/INSP/45565 dated Sep 02,2020 Trading members had displayed the set of standard documents/policies on their own website for information.

SEBI SCORES LETTER OF AUTHORITY BROKERS NORMS RMS POLICY PMLA-POLICY SURVEILLANCE POLICY KYC MANDATORY - 6 ATTRIBUTES EVoting CDSL EVoting NSDL

DISCLAIMER INACTIVE CLIENT POLICY PRIVACY POLICY TERMS & CONDITIONS COMPANY POLICIES INVESTOR GRIEVANCE REDRESSAL POLICY INVESTOR CHARTER INVESTOR CHARTER - DP INVESTOR CHARTER - RESEARCH ANALYST INVESTOR CHARTER IGC MIS ADVISORY FOR INVESTORS BNRSL-DISCLAIMERS RESEARCH REPORTS